CL

Business profile & competitive position

Colgate-Palmolive Company (CL) sits in the Consumer Defensive sector under the Household & Personal Products industry. Its business breaks into two reportable segments: Oral, Personal and Home Care (toothpaste, toothbrushes, soaps, deodorants, skin health products, cleaners and fabric conditioners) and Hill’s Pet Nutrition (specialty dog and cat foods). According to its most recent 10-K, Colgate sold products in over 200 countries and territories through retailers, wholesalers, e-commerce sellers, veterinarians and certain direct-to-consumer channels. In 2025, Oral Care alone represented 44% of worldwide net sales, Personal Care 17%, Home Care 16% and Pet Nutrition 23%.

The scale is formidable: Walmart and its affiliates accounted for roughly 11% of 2025 net sales, and no other single customer crossed the 10% threshold, which points to a diversified customer base. The company employed about 33,600 people across more than 100 countries, with over 84% of that workforce located outside the United States.

Its financial footprint tells a split story about competitive strength. The net margin is 9.7%, a respectable but not eye-popping level for a global staples leader, suggesting pricing power is offset partly by brand-building and input costs. The ROE figure of 631.1%, by contrast, is extreme; it points to a highly leveraged, asset-light capital structure rather than a pure operating-margin moat. That kind of ROE is common in mature consumer companies after years of share buybacks and debt-funded capital returns. The low beta of 0.32 underlines the defensive nature of the revenue stream—demand for toothpaste, soap and pet food does not swing with the business cycle—but it also implies the stock rarely rerates on operating leverage alone.

Financial posture

CL currently commands a $70.8 billion market capitalization and trades at a P/E ratio of 34.8. Against a 9.7% net margin, that multiple is not cheap; it prices in steady cash flow, brand durability and a premium for low volatility. The 0.32 beta confirms that investors treat the stock as a bond-proxy style holding: moves in the broader market explain very little of its day-to-day price action.

The 631.1% ROE reinforces that returns are being driven by capital-structure efficiency more than by explosive asset turns. A high-single-digit net margin in staples is healthy, but it is not the kind of figure that normally supports a mid-30s P/E unless buyers are paying for consistency, global reach and a long dividend track record rather than rapid growth.

Technically, the stock is at $88.53 with an RSI of 41.5 and a 50-day EMA of $90.39, meaning price is slightly below its short-term moving average and momentum is neutral-to-soft. That fits a defensive name that has drifted rather than rallied—valuation expansion has done more of the heavy lifting than earnings acceleration.

Strategic priorities & outlook

Colgate-Palmolive’s most recent SEC 10-K frames it as a global consumer products company with four clear priorities. First, it aims to drive organic sales growth and deliver consistent, compounded earnings-per-share growth. Second, it is focused on operational efficiencies, free cash flow generation and efficient balance-sheet use. Third, it plans to leverage global brand reach, science-based innovation, an agile supply chain and what it calls best-in-class omni-channel demand generation. Fourth, it is investing in data, analytics and artificial intelligence while building what it describes as a high-impact, inclusive culture.

The operational mix supports these goals: Oral Care is the profit engine, Pet Nutrition adds growth exposure to premiumization in pet food, and Home/Personal Care provides volume and cash flow. The fact that Walmart is the only customer above the single-digit percentage of sales highlights the importance of maintaining shelf-space dominance and retailer relationships, while the overseas employee footprint underscores why currency and emerging-market execution are embedded in the strategy.

Macro & geopolitical exposure

As a global Household & Personal Products company, CL’s macro exposures are textbook staples risks rather than company-specific surprises. Input commodities—palm oil, resins, petrochemicals, packaging materials and agricultural feed inputs for pet food—directly affect cost of goods sold. Freight, energy and logistics costs matter because the company distributes to over 200 countries. Foreign exchange risk is material: with over 84% of employees outside the U.S. and the majority of sales denominated in non-dollar currencies, a stronger U.S. dollar compresses reported revenue and earnings, while a weaker dollar flatters them.

Regulatory exposure is also inherent to the industry. Oral care, skin health, deodorant and home-care products face labeling, ingredient-safety and environmental rules that vary by country. Trade policy matters through tariffs on imported raw materials and finished goods, and consumer staples are among the first sectors targeted by subsidy or price-control debates during inflationary periods. Supply-chain resilience—referenced in the 10-K as an operational priority—is therefore not just operational; it is a macro hedge.

Recent developments

Recent headlines show Wall Street reassessing CL while the company itself appears to be pruning its portfolio. On September 11, 2026, Reuters reported that Colgate-Palmolive is seeking to divest some personal care brands, citing sources familiar with the matter. That same day, Seeking Alpha published “Colgate-Palmolive Is Recovering Nicely (Rating Upgrade),” suggesting analysts have warmed to the stock’s improving trajectory. Also on September 11, 247wallst.com listed Colgate among five dividend stocks that survived 2008, COVID and every prior recession, reinforcing its defensive reputation. On September 14, 2026, 247wallst.com followed up with “Who Buys Colgate’s Cast-Off Brands? Why the Obvious Answers Are Unlikely,” questioning who the natural buyers would be for any divested assets.

Read together, the news implies a company in transition: slimming the brand portfolio to focus on higher-return categories while investors debate whether the remaining assets deserve their premium valuation. The divestiture angle is particularly relevant to the strategic emphasis on balance-sheet efficiency and operational focus.

Earnings behavior & post-earnings drift

CL has been a serial earnings beater. Over the last eight reported quarters, it beat the published consensus every time—an 8/8, or 100%, beat rate—with an average earnings surprise of 3.3%. The average five-day price move after those reports has been 2.32% to the upside, classified as an “up” post-earnings drift.

Yet the path is not a straight one. In the four most recent quarters, the company beat estimates by 2.4% to 4.5% each time, but next-day reactions were mixed:

• July 31, 2026: actual EPS $0.99 versus estimate $0.947 (4.5% surprise) — stock fell 1.56% the next day, then rallied 2.16% over the following five days.
• May 1, 2026: actual EPS $0.97 versus estimate $0.943 (2.9% surprise) — stock fell 2.17% the next day, then drifted up only 0.33% over the following five days.
• January 30, 2026: actual EPS $0.95 versus estimate $0.912 (4.2% surprise) — stock rose 1.77% the next day and added 4.56% over the following five days.
• October 31, 2025: actual EPS $0.91 versus estimate $0.889 (2.4% surprise) — stock fell 2.69% the next day, then recovered 2.22% over the following five days.

The pattern suggests that while Colgate consistently clears the official estimate, the market’s real expectation may be higher, which is why beats sometimes trigger immediate selling. The positive five-day drift, however, indicates that once the headline is digested, buyers tend to return—perhaps because the underlying cash-flow stability reasserts itself. The next scheduled report is October 30, 2026, before the open, with a consensus EPS estimate of $0.92.

For a deeper dive into how sell-side and independent analysts are reconciling Colgate-Palmolive’s valuation, brand-divestiture plans and earnings track record, explore the full institutional verdict on the ticker page.